HIV patients should be included in early clinical trials of anti-TB drugs

Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide, yet the majority of these patients are excluded from the early stages in the development of new, anti-tuberculosis drugs. Some TB drugs have drug interactions with anti-retroviral drugs, and so the compatibility of new TB drugs with concomitant anti-retroviral treatment should be investigated early in the clinical development, according to the new research.
Source :      2015/10/3 09:26

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.